Experimental Normothermic and Hyperthermic Intraperitoneal Perfusion Chemotherapy of Advanced Ovarian Cancer


Cite item

Full Text

Abstract

Relevance The search and development of effective regimens of normothermic and hyperthermic intraperitoneal chemoperfusion (IPEC and HIPEC) in experiment will allow implementing the technology into clinical practice to treat patients with advanced ovarian cancer and therefore increase their survival.
The purpose of the study The development of preclinical model of normo- and hyperthermic chemoperfusion treatment of advanced ovarian cancer and assessment of efficiency of alkylating cytostatics at their intraperitoneal chemoperfusion administration.
Materials and methods The study was carried out in 295 Vistar female rats with ovarian cancer which was inoculated intraperitoneally. IPEC and HIPEC were performed with antitumor drugs cisplatin and dioxadet in maximum tolerated doses (MTD) which were 5−20 times higher than those for the standard intraperitoneal administration of the drugs. Antitumor effects of the treatment were estimated in increase of median survival time (MST).
Results and their discussion Hyperthermic intraperitoneal perfusion (HIPEP) with saline solution showed significant antitumor activity comparable to effects of intraperitoneal administration of cisplatin and dioxadet. HIPEC with the drugs resulted in larger number of side effects compared to IPEC. Potentiation of antitumor effect of dioxadet and hyperthermia was achieved for HIPEC with dioxadet, where increase in MST of rats was the greatest among all experimental groups – 444% compared to the control group (p=0.038).
Conclusion The developed experimental technology of IPEC and HIPEC is recommended for testing of different cytostatic drugs and new methods of intraperitoneal chemoperfusion treatment of malignancies affecting peritoneum.

About the authors

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Author for correspondence.
Email: galinakireyeva@mail.ru
laboratory researcher in the department of chemoprevention of cancer and oncopharmacology of N.N. Petrov Research Institute of Oncology

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
researcher in the department of chemoprevention of cancer and oncopharmacology of N.N. Petrov Research Institute of Oncology, PhD

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
head of the department of chemoprevention of cancer and oncopharmacology of N.N. Petrov Research Institute of Oncology, MD, PhD

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
 leading researcher of the department of anesthesiology, intensive care and palliative oncology of N.N. Petrov Research Institute of Oncology, MD, PhD

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
junior researcher in the department of chemoprevention of cancer and oncopharmacology of N.N. Petrov Research Institute of Oncology

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
senior researcher in the department of chemoprevention of cancer and oncopharmacology of N.N. Petrov Research Institute of Oncology, MD, PhD

N.N. Petrov Research Institute of Oncology, 68 Leningradskaia Str., Saint-Petersburg, 197758,
Russian Federation

Email: admin@vestnik-surgery.com
director of N.N. Petrov Research Institute of Oncology, MD, PhD, professor

References

  1. Belyaeva O.A. Chemoperfusionnoe lecheniye zlokachestvennykh novoobrazovaniy. [Chemoperfusion treatment of malignancies]. Medline express, 2011; 2–3: 58–65. - (In Russ.).
  2. Bespalov V.G. Sravnitel'noye izucheniye protivoopukholevykh effektov tsitostatikov v astsiticheskoy zhidkosti v modeli raka yaichnikov. [Comparative study of antitumor effects of cytostatic drugs in ascitic ovarian cancer model.] Medline express, 2011; 2–3: 48–52. - (In Russ.).
  3. Chissov V.I., Starinsky V.V., Petrova G.V. (eds.) Zlokachestvennye novoobrazovaniia v Rossii v 2011 godu (zabolevaemost' i smertnost') [Malignant Neoplasms in Russia in 2011 (Morbidity and Mortality)]. Moscow, 2013; 230. - (In Russ.).
  4. Stukov A.N., Gershanovich M.L., Blank M.A. et al. Protivoopukholevye lekarstvennye sredstva [Antineoplastic agents]. Saint-Petersburg: NIKA, 2011; 656. - (In Russ.).
  5. Chua T.C., Robertson G., Liauw W., Farrell R., Yan T.D., Morris D.L. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J. Cancer Res. Clin. Oncol., 2009; 135: 1637–1645.
  6. E. de Bree, Helm C.W. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev. Anticancer Ther., 2012; 12: 7: 895–911.
  7. Dudar T.E., Jain R.K. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res., 1984; 44: 605–612.
  8. Ferlay J., Shin H.R., Bray F. et al. Cancer incidence and mortality worldwide. IARC Cancer Base №10. Lyon, France: International Agency for Research on Cancer. – 2010. [Electronic source]. Avaliable at: http://globocan.iarc.fr.
  9. Helm C.W., Richard S.D., Pan J. et al. HIPEC in ovarian cancer: first report of HYPER-O registry. International Journal of Gynecological Cancer, 2010; 20: 1: 61–69.
  10. Hildebrandt B., Wust P., Ahlers O., Dieing A., Sreenivasa G., Kerner T., Felix R., Riess H. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol., 2002; 43: 33–56.
  11. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin., 2010; 60: 277–300.
  12. Klaver Y.L., Hendriks T., Lomme R.M., Rutten H.J., Bleichrodt R.P., de Hingh I.H. Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study. Ann. Surg., 2011; 254: 1: 125–130.
  13. Issels R.D. Hyperthermia adds to chemotherapy. Eur. J. Cancer, 2008; 44: 2546–2554.
  14. Sticca R.P., Dach B.W. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg. Oncol. Clin. N. Am., 2003; 12: 689–701.
  15. Yan T.D., Zappa L., Edwards G., Alderman R., Marquardt C.E., Sugarbaker P.H. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J. Surg. Oncol., 2007; 96: 102–112.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 ., ., ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies